CA
NZ
UK
AU
IND
US
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has reported a narrower net loss for the second quarter of 2026, posting an EPS of $-2.87 compared to a consensus estimate of $-3.73. The decrease in losses highlights potential investor confidence amid a competitive environment, suggesting that …
Precision BioSciences, Inc. (NASDAQ: DTIL) announced a second-quarter EPS of $-0.75, falling short of the $-0.67 consensus estimate, highlighting challenges in its path to profitability. This result contrasts the strong performance of the previous quarter, where the company faced an uphill battle in securing …
Prime Medicine, Inc. (NASDAQ: PRME) reported a second-quarter earnings per share (EPS) of $-0.24, a slight increase compared to the $-0.26 consensus estimate. The announcement on August 6, 2026, underscored the company's emphasis on advancing its innovative gene therapies. PRME reported a net loss …
Privia Health Group, Inc. (NASDAQ: PRVA) reported a compelling net income of $9.0 million for the second quarter of 2026, representing a remarkable increase of 236.7% compared to the same period last year. This acceleration in profitability aligns with the consensus EPS estimate of …
This substantial drop is primarily due to the prior year's impressive figures, which included a $175 million milestone from the Nuvaxovid vaccine's Biologics License Application approval. Despite this decline, Novavax exceeded analyst expectations, reporting an earnings per share (EPS) loss of $-0.32, which was …
Year-to-date, the company’s stock has decreased by 26.9%, despite a 6.9% recovery over the past month, indicating potential volatility. Market conditions and the broader sector’s performance could influence Nuvation Bio's future trajectory. Achieving this slightly better-than-expected EPS may temper investor concerns, suggesting a cautiously …
Lantheus Holdings, Inc. (NASDAQ: LNTH) reported strong financial results for the second quarter, achieving worldwide revenue of $388.2 million, reflecting a 2.7% increase compared to $378.0 million in the same quarter last year. This revenue figure exceeded the consensus estimates, following earlier reports where …
The missed expectation comes as the company continues to navigate complex clinical timelines, particularly as it prepares for the resubmission of its New Drug Application (NDA) for ZYNQUISTA in type 1 diabetes later this year. The company’s stock has risen 109.2% year-to-date, reflecting investor …
LifeStance Health Group, Inc. (NASDAQ: LFST) posted second-quarter revenue of $435.4 million, a significant 26% increase compared to $345.3 million in the same period last year. The company also announced a $100 million share repurchase program, replacing its previous repurchase plan. LifeStance exceeded analyst …
Ligand Pharmaceuticals reported a significant increase in royalty revenue for Q2 2026, reaching $48 million. This figure represents a strong 32% growth compared to the same quarter last year, driven primarily by higher earnings from key products like Travere Therapeutics’ Filspari and Pelthos Therapeutics’ …
Please wait processing your request...